Robarts Research Institute

Carestream Collaborates with Robarts Research Institute To Advance Translational Cardiothoracic and Pulmonary Disease Research

Retrieved on: 
Tuesday, February 7, 2023
Cardiology, Biotechnology, Other Health, Health, General Health, Radiology, Health Technology, Medical Devices, Research, Hospitals, Science, Associate professor, Robarts, Physician, Medical imaging, Anatomy, Robarts Research Institute, CT, Acquisition, DT, Patient, Lung, DE, Software, Doctor of Philosophy, Intelligence, Partnership, Innovation, Radiography, Multimedia, Intelligence Advanced Research Projects Activity, Tomosynthesis, Schulich School of Medicine & Dentistry, Western University, Medical physics, Medicine, Nursing, Pharmaceutical industry, Carestream Health

Carestream Health is partnering with Robarts Research Institute to increase and demonstrate the clinical value of digital X-ray, digital tomosynthesis and dual energy technologies to help improve the outcomes of patients with cardiothoracic and pulmonary diseases.

Key Points: 
  • Carestream Health is partnering with Robarts Research Institute to increase and demonstrate the clinical value of digital X-ray, digital tomosynthesis and dual energy technologies to help improve the outcomes of patients with cardiothoracic and pulmonary diseases.
  • Carestream is providing a state-of-the-art imaging system and software to Robarts, the research institute of Schulich School of Medicine & Dentistry at Western University in Canada, to advance its multidisciplinary translational research.
  • View the full release here: https://www.businesswire.com/news/home/20230207005386/en/
    Carestream Health is partnering with Robarts Research to demonstrate the clinical value of digital tomosynthesis and dual energy technologies to help improve patient outcomes.
  • (Graphic: Business Wire)
    The equipment installed at Robarts mirrors what is found in the region’s clinical settings and will support collaborative, multidisciplinary research that bridges bench to bedside.

Boston Heart Diagnostics Launches LipidSeq™-- An NGS Test for Common Genetic Disorders of Lipid Metabolism

Retrieved on: 
Wednesday, August 17, 2022
LCAT, Robarts Research Institute, Triglyceride, Cardiovascular disease, Multimedia, Disorder, Risk, Apolipoprotein, Lists of diseases, Hypercholesterolemia, HDL, Lipid metabolism, Tangier disease, Hypertriglyceridemia, Patient, View, NGS, Kidney, Sitosterolemia, Mutation, Lipidology, Health, Disease, Health care, Pharmaceutical industry, Eurofins Scientific, Familial dysbetalipoproteinemia

This saliva-based NGS test identifies the most common genetic causes of lipid and lipoprotein disorders.

Key Points: 
  • This saliva-based NGS test identifies the most common genetic causes of lipid and lipoprotein disorders.
  • Boston Heart Diagnostics announces the launch of LipidSeq, a revolutionary genetic test for cardiovascular disease.
  • Boston Heart is the only commercial laboratory able to test biochemical and genetic contributors when diagnosing inherited disorders of lipid metabolism (Reference: Schaefer EJ, Geller AS, Endress G. The biochemical and genetic diagnosis of lipid disorders.
  • For more information on Boston Heart Diagnostics, please visit www.BostonHeartDiagnostics.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/boston-heart-diagnostics-launch...

Magnetic Insight Raises $17M Series B to Expand Magnetic Particle Imaging and Monitoring Technology into Clinical Applications

Retrieved on: 
Thursday, June 23, 2022
Momentum, Doctor of Philosophy, Computer Sciences, NK, CTO, Nuclear medicine, Wenzhou Medical University, University of New South Wales, Technology, Lymphoma, CEO, Robarts Research Institute, Johns Hopkins University, Biological engineering, Stanford University School of Medicine, Cancer, Cook, Growth, Karolinska Institute, Physician, Lymphatic system, University, CT, University of Florida, Celesta, MRI, Leukemia, MPI, Magnetic particle imaging, Patient, Academic health science centre, Health, Electricity, University of California, Berkeley, Michigan State University, Medical imaging

ALAMEDA, Calif., June 23, 2022 /PRNewswire/ -- Imaging diagnostics company Magnetic Insight today announced $17 million in Series B funding led by Celesta Capital, with participation from Alumni Ventures Group, Gaingels, and others, along with existing investors 5AM Ventures and Sand Hill Angels. The funding will support Magnetic Insight's continued growth and expansion of its innovative Magnetic Particle Imaging (MPI) technology into clinical applications.

Key Points: 
  • The funding will support Magnetic Insight's continued growth and expansion of its innovative Magnetic Particle Imaging (MPI) technology into clinical applications.
  • Magnetic Insight's goal is to offer clinicians a method to directly monitor cell therapy, enabling better and earlier clinical decisions, and optimal clinical outcomes.
  • Magnetic Insight has pioneered magnetic particle imaging (MPI), a new diagnostic and monitoring technology that transforms medical imaging.
  • Having started in the preclinical space by selling small animal products to leading universities worldwide, Magnetic Insight is now scaling up MPI technology for clinical use.

Biotech Support Group & Lawson Health Research Institute Enter Collaborative Research Agreement to Monitor Protease Inhibitor Function During Covid-19 Infections

Retrieved on: 
Tuesday, September 28, 2021
Blood, Peptide, ASMS, Goal, Business development, Partnership, Ingo Nugel, Robarts Research Institute, Research, Protein, Mass spectrometry, Patient, Protease, Risk, Partner, LC-MS, Lawson Health Research Institute, Infection, Inflammation, Health, Immunity, Society, Conference, Doctor of Philosophy, Cancer, COVID-19, Poster, Immunoglobulin G, Coagulation, MD, Western University, Biomarker, Business, Method, BSG, Medicine, Proteomics, Growth, Digestion, Disease, Type, Science, Founder, Severe acute respiratory syndrome coronavirus 2, Thrombosis, Lawson, Hospital, Degenerative disease, Enzyme, Intellectual property, Industry, American Society for Mass Spectrometry, Pharmaceutical industry, Vaccine

MONMOUTH JUNCTION, N.J. and LONDON, Ontario, Sept. 28, 2021 /PRNewswire-PRWeb/ -- Biotech Support Group and Lawson Health Research Institute announce a collaborative research agreement.

Key Points: 
  • MONMOUTH JUNCTION, N.J. and LONDON, Ontario, Sept. 28, 2021 /PRNewswire-PRWeb/ -- Biotech Support Group and Lawson Health Research Institute announce a collaborative research agreement.
  • The agreement supports further research to monitor protease inhibitor function acquired from blood collected from hospitalized patients with the SARS-CoV-2 (COVID-19) virus.
  • Lawson Health Research Institute is one of Canada's top hospital-based research institutes, tackling the most pressing challenges in health care.
  • As the research institute of London Health Sciences Centre and St. Joseph's Health Care London, our innovation happens where care is delivered.